{"disease":{"id":"blastomycosis","name":"Blastomycosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"itraconazole","indication_name":"Blastomycosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Blastomycosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"ketoconazole","indication_name":"Blastomycosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nizoral","generic_name":"ketoconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1","drug_class":"Azole Antifungal [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ketoconazole","indication_name":"Chromoblastomycosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nizoral","generic_name":"ketoconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1","drug_class":"Azole Antifungal [EPC]","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001702","title":"Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT06523998","title":"A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Caja Costarricense de Seguro Social","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}